

Your Latest Ophthalmology News for Ophthalmic Drugs 2018

LONDON, UNITED KINGDOM, June 26, 2018 /EINPresswire.com/ -- Did you know...

the global [ophthalmic](#) drug market is projected to reach £30 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023.

Ophthalmic News:

Elasmogen: Dr Caroline Barelle named "Rising Stars: Extraordinary Talent"

The CEO of Elasmogen, Dr Caroline Barelle was named as the winner in the "Rising Stars: Extraordinary Talent (2017)" category at Scotland's Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland's top Life Sciences industry leaders on 16 May 2018.

Dr Barelle founded Elasmogen Ltd in 2016 and has rapidly established the company as a global biotech with an international profile and late-stage, pre-clinical products positioned to make a "sight-saving" difference in ophthalmology. This award also recognises Dr Barelle's success at securing collaborative partnerships with companies that include Almac Discovery Ltd and the US bio-pharmaceutical giant, Amgen Inc.

Join Caroline this November, as she presents: 'soloMERs™ - Site-specific Biologics for Ocular Disease.'

Details below:

- Advantages of soloMERs
- Isolation and characterisation of target specific soloMERs
- Efficacy in pre-clinical models of disease
- Elasmogen's ocular portfolio

Spark Therapeutics: A Constellation of Inherited Retinal Diseases (IRDs)

Inherited retinal diseases (also called inherited retinal dystrophies, or IRDs) are a group of rare eye disorders caused by an inherited gene mutation and can result in vision loss or blindness. The



conditions vary, but those with IRDs may face many similar challenges, including night blindness (nyctalopia), declining vision, or blindness at birth.

Explore the future of ocular gene editing in inherited retinal diseases as Dr. Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics presents: 'New horizon for treatment of inherited retinal dystrophy.'

Details below:

- Voretigene: The first gene therapy approved in ophthalmology
- Other up-coming gene therapy trials in the pipeline
- Market access difficulties for gene therapy

Alimera Sciences: Retinal Diseases - Moving the back of the eye to the forefront of research and development

At Alimera Sciences retinal disease is kept at the forefront. Their commitment to retina specialists and their patients is manifest in the product and development portfolio which is designed to treat early- and late-stage diseases such as diabetic macular edema.

Philip Ashman, Senior Vice President, Managing Director Europe, Alimera Sciences will examine: 'The challenge of replicating clinical trial performance of intravitreal therapies in the ophthalmology clinic.'

Details below:

- Review the development of practice in treatment of diabetic macular oedema
- The challenges of accepting innovation into everyday practice
- The emergence of "Real-World" data collection and lessons learned
- A look into the future

Download a copy of the [agenda](#) online for full details on all presentations

Event Info:

Some other notable areas of interest are current unmet needs for geographic atrophy, genetically defined therapies in AMD, preservative free and connected devices and other novel drug delivery strategies.

The event will address the impact of the overwhelming digitalisation such as artificial intelligence in drug discovery and how companies, from biotech's to pharma, need to adapt. It will also explore new strategies for treating retinal vascular diseases, the future of ocular gene editing and a regulatory perspective of the industry.

Hear from opinion leaders such as Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics, Santen + more.

For those looking to attend, there is currently a £300 early-bird saving, ending June 29th.

Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the [attendee](#) list from last year at: www.opthalmicdrugs.com/ein

SMi presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.opthalmicdrugs.com/ein

Sponsors: Experimentica | Nemera

Follow 'SMi Pharma' on LinkedIn for latest pharmaceutical industry updates.

Sources: Allied Market Research | Elasmogen | aSharedVision | Alimera Sciences

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki
SMi Group
2078276048
[email us here](mailto:psolanki@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.